Heron Therapeutics (HRTX) Cash & Equivalents (2010 - 2026)

Heron Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 169.05% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (up 169.05% YoY), and the FY2025 full-year result was $11.6 million, up 510.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $11.3 million, down from $11.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $50.4 million in Q3 2022, with the low at $1.5 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $13.5 million across 5 years, with a median of $11.5 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 98.34% — and 2025, when it jumped 510.53%.
• Heron Therapeutics' Cash & Equivalents stood at $1.5 million in 2022, then jumped by 253.33% to $5.3 million in 2023, then plunged by 64.15% to $1.9 million in 2024, then jumped by 510.53% to $11.6 million in 2025, then fell by 2.59% to $11.3 million in 2026.
• The last three Cash & Equivalents figures came in at $11.3 million (Q1 2026), $11.6 million (Q4 2025), and $16.9 million (Q3 2025), per Business Quant data.